Edward P. Garvey

6.3k citations

82 papers · 5.1k indexed · 1 hit paper · h-index 39

Co-authors: Eric S. Furfine Jeffrey A. Oplinger Robert J. Schotzinger Daniel V. Santi Richard G. Knowles B.J.R. Whittle Ferenc László William J. Hoekstra
Topics: Antifungal resistance and susceptibility (29 papers)Fungal Infections and Studies (21 papers)Biochemical and Molecular Research (19 papers)
Cited by: Virology Infectious Diseases Biochemistry
Journals: Science Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States United Kingdom Japan

In The Last Decade

Edward P. Garvey

82 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo

1997 727 citations Edward P. Garvey, Jeffrey A. Oplinger et al. Journal of Biological Chemistry profile →

Peers

Countries citing papers authored by Edward P. Garvey

Since Specialization

Citations

This map shows the geographic impact of Edward P. Garvey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward P. Garvey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward P. Garvey more than expected).

Fields of papers citing papers by Edward P. Garvey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Edward P. Garvey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward P. Garvey. The network helps show where Edward P. Garvey may publish in the future.

Co-authorship network of co-authors of Edward P. Garvey

This figure shows the co-authorship network connecting the top 25 collaborators of Edward P. Garvey. A scholar is included among the top collaborators of Edward P. Garvey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Edward P. Garvey. Edward P. Garvey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Safety and pharmacokinetics of antifungal agent VT-1598 and its primary metabolite, VT-11134, in healthy adult subjects: phase 1, first-in-human, randomized, double-blind, placebo-controlled study of single-ascending oral doses of VT-1598 2024 ·Medical Mycology ·(unknown),Robert W. Spitz,(unknown),(unknown),Varduhi Ghazaryan,Edward P. Garvey,Thorsten P. Degenhardt	7
2	Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus 2017 ·Journal of Antimicrobial Chemotherapy ·Nathan P. Wiederhold,Hoja Patterson,(unknown),Christopher M. Yates,Robert J. Schotzinger,Edward P. Garvey	56
3	Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors 2017 ·Bioorganic & Medicinal Chemistry Letters ·Christopher M. Yates,Edward P. Garvey,Sammy R. Shaver,Robert J. Schotzinger,William J. Hoekstra	71
4	Activity of VT-1129 againstCryptococcus neoformansclinical isolates with high fluconazole MICs 2016 ·Medical Mycology ·Kirsten Nielsen,(unknown),Kyle D. Smith,David B. Meya,Edward P. Garvey,William J. Hoekstra,Robert J. Schotzinger,David R. Boulware	23
5	The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme 2014 ·Antimicrobial Agents and Chemotherapy ·Andrew G. S. Warrilow,Claire M. Hull,Josie E. Parker,Edward P. Garvey,W. HOEKSTRA,William R. Moore,Robert J. Schotzinger,Diane Kelly,Steven L. Kelly	134
6	Naphthyridinone (NTD) integrase inhibitors 4. Investigating N1 acetamide substituent effects with C3 amide groups 2014 ·Bioorganic & Medicinal Chemistry Letters ·Brian A. Johns,Takashi Kawasuji,Jason G. Weatherhead,Eric E. Boros,James B. Thompson,Cecilia S. Koble,Edward P. Garvey,Scott A. Foster,Jerry Jeffrey,Tamio Fujiwara	5
7	Design and optimization of highly-selective fungal CYP51 inhibitors 2014 ·Bioorganic & Medicinal Chemistry Letters ·William J. Hoekstra,Edward P. Garvey,William R. Moore,(unknown),Christopher M. Yates,Robert J. Schotzinger	152
8	Combining symmetry elements results in potent naphthyridinone (NTD) HIV-1 integrase inhibitors 2011 ·Bioorganic & Medicinal Chemistry Letters ·Brian A. Johns,Takashi Kawasuji,Jason G. Weatherhead,Eric E. Boros,James B. Thompson,Edward P. Garvey,Scott A. Foster,Jerry Jeffrey,Wayne H. Miller,Noriyuki Kurose,(unknown),Tamio Fujiwara	6
9	The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore 2009 ·Bioorganic & Medicinal Chemistry Letters ·Brian A. Johns,Jason G. Weatherhead,Scott H. Allen,James B. Thompson,Edward P. Garvey,Scott A. Foster,Jerry Jeffrey,Wayne H. Miller	94
10	Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics 2008 ·Antiviral Research ·Koichiro Nakahara,Chiaki Wakasa-Morimoto,Masanori Kobayashi,Shigeru Miki,Takeshi Noshi,Takahiro Seki,(unknown),(unknown),(unknown),Toshio Fujishita,Tomokazu Yoshinaga,Edward P. Garvey,Brian A. Johns,Scott A. Foster,Mark Underwood,Akihiko Sato,Tamio Fujiwara	46
11	Synthesis and HIV-integrase strand transfer inhibition activity of 7-hydroxy[1,3]thiazolo[5,4-b]pyridin-5(4H)-ones 2006 ·Bioorganic & Medicinal Chemistry Letters ·Eric E. Boros,Brian A. Johns,Edward P. Garvey,Cecilia S. Koble,Wayne H. Miller	37
12	GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo 2005 ·British Journal of Pharmacology ·W. Alderton,(unknown),(unknown),John Dawson,Edward P. Garvey,Salvador Moncada,(unknown),Daryl D. Rees,Linda Russell,Rachel Russell,(unknown),(unknown),Richard G. Knowles	77
13	Small molecule modulators of HIV Rev/Rev response element interaction identified by random screening 2002 ·Antiviral Research ·(unknown),Thomas B. Stanley,Richard Hazen,Edward P. Garvey	41
14	Response of the septic vasculature to prolonged vasopressor therapy with N (omega-monomethyl-L-arginine) and epinephrine in canines 1998 ·Critical Care Medicine ·Bradley D. Freeman,Fabrice Zéni,Steven M. Banks,Peter Q. Eichacker,John Bacher,Edward P. Garvey,Joel V. Tuttle,Cynthia H. Jurgensen,Charles Natanson,Robert L. Danner	11
15	1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivobreakdown → 1997 ·Journal of Biological Chemistry ·Edward P. Garvey,Jeffrey A. Oplinger,Eric S. Furfine,(unknown),Ferenc László,B.J.R. Whittle,Richard G. Knowles	727
16	Purification and inhibitor screening of human nitric oxide synthase isozymes 1996 ·Methods in enzymology on CD-ROM/Methods in enzymology ·Edward P. Garvey,Eric S. Furfine,Paula Sherman	10
17	Purification and Characterization of the Constitutive Nitric-Oxide Synthase from Human Placenta 1994 ·Archives of Biochemistry and Biophysics ·Edward P. Garvey,Joel V. Tuttle,(unknown),B M Merrill,Edgar R. Wood,(unknown),Ian G. Charles	89
18	A novel human phosphotransferase highly specific for adenosine 1992 ·Archives of Biochemistry and Biophysics ·Edward P. Garvey,Thomas A. Krenitsky	10
19	Transient intermediates in the folding of dihydrofolate reductase as detected by far-ultraviolet circular dichroism spectroscopy 1991 ·Biochemistry ·Kunihiro Kuwajima,Edward P. Garvey,Bryan E. Finn,C. Robert Matthews,Shintaro Sugai	130
20	Effects of multiple replacements at a single position on the folding and stability of dihydrofolate reductase from Escherichia coli 1989 ·Biochemistry ·Edward P. Garvey,C. Robert Matthews	59

About Edward P. Garvey

Edward P. Garvey is a scholar working on Virology, Infectious Diseases and Biophysics, having authored 82 papers that have together received 5.1k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (29 papers), Fungal Infections and Studies (21 papers) and Biochemical and Molecular Research (19 papers). The work is most often cited by research in Virology (655 citations), Infectious Diseases (1.9k citations) and Biochemistry (469 citations). Edward P. Garvey has collaborated with scholars based in United States, United Kingdom and Japan. Frequent co-authors include Eric S. Furfine, Jeffrey A. Oplinger, Robert J. Schotzinger, Daniel V. Santi, Richard G. Knowles, B.J.R. Whittle, Ferenc László, William J. Hoekstra, Christopher M. Yates and C. Robert Matthews. Their work appears in journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact